US OptionsDetailed Quotes
PSNL250117C10000
- 0.20
- 0.000.00%
15min DelayTrading Dec 24 10:19 ET
0.00High0.00Low
0.00Open0.20Pre Close0 Volume33 Open Interest10.00Strike Price0.00Turnover204.16%IV51.11%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.1789Delta0.1084Gamma33.75Leverage Ratio-0.0281Theta0.0003Rho6.04Eff Leverage0.0031Vega
Personalis Stock Discussion
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Thursday, 19th December at 9:00 am
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Mode...
Personalis and Tempus Expand Collaboration to Biopharma
Monday, 16th December at 8:00 am
Expanded collaboration to yield greater biopharma access to Personalis' MRD solution
Personalis, Inc. (NASDAQ: PSNL) and Tempus AI, Inc. (NASDAQ: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Soc...
📊⚡️📊
In a world where technological advancements continually reshape the landscape of healthcare, collaboration among industry leaders plays a pivotal role in accelerating innovation. A testament to this is the expanded collaboration between Personalis, Inc., a renowned leader in cancer genomics, and Tempus AI, Inc., a technology-driv...
📊⚡️📊
No comment yet